PL3413870T3 - Igmezyna do zastosowania do leczenia choroby alzheimera - Google Patents
Igmezyna do zastosowania do leczenia choroby alzheimeraInfo
- Publication number
- PL3413870T3 PL3413870T3 PL17704271T PL17704271T PL3413870T3 PL 3413870 T3 PL3413870 T3 PL 3413870T3 PL 17704271 T PL17704271 T PL 17704271T PL 17704271 T PL17704271 T PL 17704271T PL 3413870 T3 PL3413870 T3 PL 3413870T3
- Authority
- PL
- Poland
- Prior art keywords
- igmesine
- alzheimer
- disease
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662293832P | 2016-02-11 | 2016-02-11 | |
| EP17704271.0A EP3413870B1 (en) | 2016-02-11 | 2017-02-10 | Igmesine for use in the treatment of alzheimer's disease |
| PCT/EP2017/053066 WO2017137600A1 (en) | 2016-02-11 | 2017-02-10 | Igmesine for use in the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3413870T3 true PL3413870T3 (pl) | 2022-01-10 |
Family
ID=58009847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17704271T PL3413870T3 (pl) | 2016-02-11 | 2017-02-10 | Igmezyna do zastosowania do leczenia choroby alzheimera |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11129801B2 (pl) |
| EP (2) | EP3903767A1 (pl) |
| JP (1) | JP7059192B2 (pl) |
| CN (1) | CN109069414B (pl) |
| AU (1) | AU2017218592B2 (pl) |
| CA (1) | CA3012415C (pl) |
| CY (1) | CY1124821T1 (pl) |
| DK (1) | DK3413870T3 (pl) |
| ES (1) | ES2895957T3 (pl) |
| HR (1) | HRP20211661T1 (pl) |
| HU (1) | HUE056265T2 (pl) |
| LT (1) | LT3413870T (pl) |
| PL (1) | PL3413870T3 (pl) |
| PT (1) | PT3413870T (pl) |
| RS (1) | RS62615B1 (pl) |
| SI (1) | SI3413870T1 (pl) |
| WO (1) | WO2017137600A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3903767A1 (en) | 2016-02-11 | 2021-11-03 | SigmaThera SAS | Igmesine for use in the treatment of neurodegenerative diseases |
| EP4404933A1 (en) * | 2021-09-20 | 2024-07-31 | Esteve Pharmaceuticals, S.A. | Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection |
| FR3149773B1 (fr) | 2023-06-19 | 2026-04-17 | Rest Therapeutics | Nouvelles combinaisons synergiques a base de fenm |
| JP7626488B1 (ja) * | 2023-10-11 | 2025-02-04 | 株式会社アイビー化粧品 | Ｍａｏ阻害剤 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4607824A (en) | 1983-01-11 | 1986-08-26 | Energy Absorption Systems, Inc. | Guardrail end terminal |
| FR2636625B1 (fr) | 1988-09-01 | 1990-11-09 | Jouveinal Sa | Benzylamines disubstituees, leur procede de preparation, leur utilisation comme medicament et leurs intermediaires de synthese |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| JP4600610B2 (ja) * | 1996-05-15 | 2010-12-15 | 株式会社フジモト・コーポレーション | アセチルコリン系神経伝達改善剤 |
| WO2000041684A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | A pharmaceutical combination for the treatment of depression |
| EP1078630A1 (en) | 1999-08-27 | 2001-02-28 | Warner-Lambert Company | Use of sigma receptor agonists for the treatment of depression |
| US6436938B1 (en) | 2001-01-22 | 2002-08-20 | Pfizer Inc. | Combination treatment for depression |
| JP2004532868A (ja) * | 2001-05-25 | 2004-10-28 | シェーリング コーポレイション | アルツハイマー病の処置におけるアゼチジノン置換誘導体の使用 |
| US20050070524A1 (en) | 2003-06-06 | 2005-03-31 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
| CN100420483C (zh) * | 2003-06-12 | 2008-09-24 | 株式会社爱慕知科学 | 用于神经元再生和功能恢复的σ配体 |
| EP1644026A4 (en) | 2003-06-12 | 2007-10-24 | Ms Science Corp | SIGMA LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RECREATION |
| CN1960781A (zh) * | 2004-04-14 | 2007-05-09 | 沃尼尔·朗伯有限责任公司 | 治疗阿尔茨海默氏病的治疗组合 |
| WO2006133199A2 (en) * | 2005-06-06 | 2006-12-14 | University Of South Florida | Treatment with sigma receptor agonists post-stroke |
| FR2970869B1 (fr) * | 2011-01-31 | 2013-09-06 | Centre Nat Rech Scient | Utilisation du recepteur sigma-1 pour reguler l'expression des canaux ioniques au niveau post-transcriptionnel |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| EP3903767A1 (en) | 2016-02-11 | 2021-11-03 | SigmaThera SAS | Igmesine for use in the treatment of neurodegenerative diseases |
-
2017
- 2017-02-10 EP EP21181531.1A patent/EP3903767A1/en not_active Withdrawn
- 2017-02-10 RS RS20211350A patent/RS62615B1/sr unknown
- 2017-02-10 US US16/076,504 patent/US11129801B2/en active Active
- 2017-02-10 HU HUE17704271A patent/HUE056265T2/hu unknown
- 2017-02-10 HR HRP20211661TT patent/HRP20211661T1/hr unknown
- 2017-02-10 WO PCT/EP2017/053066 patent/WO2017137600A1/en not_active Ceased
- 2017-02-10 PT PT177042710T patent/PT3413870T/pt unknown
- 2017-02-10 PL PL17704271T patent/PL3413870T3/pl unknown
- 2017-02-10 SI SI201730963T patent/SI3413870T1/sl unknown
- 2017-02-10 EP EP17704271.0A patent/EP3413870B1/en active Active
- 2017-02-10 LT LTEPPCT/EP2017/053066T patent/LT3413870T/lt unknown
- 2017-02-10 JP JP2018543150A patent/JP7059192B2/ja active Active
- 2017-02-10 AU AU2017218592A patent/AU2017218592B2/en active Active
- 2017-02-10 DK DK17704271.0T patent/DK3413870T3/da active
- 2017-02-10 CN CN201780021077.9A patent/CN109069414B/zh active Active
- 2017-02-10 CA CA3012415A patent/CA3012415C/en active Active
- 2017-02-10 ES ES17704271T patent/ES2895957T3/es active Active
-
2021
- 2021-10-26 CY CY20211100929T patent/CY1124821T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2895957T3 (es) | 2022-02-23 |
| JP7059192B2 (ja) | 2022-04-25 |
| HRP20211661T1 (hr) | 2022-02-18 |
| AU2017218592B2 (en) | 2022-10-20 |
| LT3413870T (lt) | 2021-11-10 |
| CN109069414A (zh) | 2018-12-21 |
| PT3413870T (pt) | 2021-09-10 |
| CA3012415A1 (en) | 2017-08-17 |
| EP3413870B1 (en) | 2021-08-04 |
| HUE056265T2 (hu) | 2022-02-28 |
| EP3903767A1 (en) | 2021-11-03 |
| US20190046472A1 (en) | 2019-02-14 |
| CN109069414B (zh) | 2022-01-14 |
| CA3012415C (en) | 2024-03-12 |
| CY1124821T1 (el) | 2022-11-25 |
| EP3413870A1 (en) | 2018-12-19 |
| US11129801B2 (en) | 2021-09-28 |
| DK3413870T3 (da) | 2021-11-01 |
| JP2019504872A (ja) | 2019-02-21 |
| AU2017218592A1 (en) | 2018-08-09 |
| WO2017137600A1 (en) | 2017-08-17 |
| SI3413870T1 (sl) | 2021-12-31 |
| RS62615B1 (sr) | 2021-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE063369T2 (hu) | Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben | |
| IL263188B (en) | Treatment for Parkinson's disease | |
| SMT202300250T1 (it) | Trattamento della malattia di alzheimer in una particolare popolazione di pazienti | |
| CY1127309T1 (el) | Ebselen για χρηση στη θεραπεια της νοσου meniep | |
| ES3064246T3 (en) | Compounds for use in methods for treating alzheimer's disease | |
| IL265911A (en) | Epilimod preparations and methods of using them in the treatment of Alzheimer's disease | |
| PL3413870T3 (pl) | Igmezyna do zastosowania do leczenia choroby alzheimera | |
| IL264040A (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
| IL254252A0 (en) | History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease | |
| PL3137097T3 (pl) | Leczenie i profilaktyka choroby Alzheimera (AD) | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| EP3162377A4 (en) | Use of -asarone in preparing drugs for preventing and treating alzheimer's disease | |
| PL3137094T3 (pl) | Leczenie i profilaktyka choroby alzheimera (ad) | |
| IL262902A (en) | Prion protein-dendrimer conjugates for use in treatment of alzheimer disease | |
| SG11201607693WA (en) | 6-substituted estradiol derivatives for the treatment of alzheimer's disease | |
| HUE037501T2 (hu) | Alzheimer-kór (AD) kezelése és megelõzése | |
| ZA201808361B (en) | Benzoxazine or quinazoline derivatives for use in the treatment of alzheimer¿s disease | |
| ZA201801945B (en) | Compositions and methods for the treatment of parkinson's disease | |
| GB201710410D0 (en) | Inorganic polyphosphate formulations for use in the treatment of alzheimer disease | |
| GB201603510D0 (en) | Compositions for use in the treatment of neurological disease | |
| ZA201807944B (en) | Treatment for parkinson's disease | |
| HK40013419A (en) | Apilimod compositions and methods for using same in the treatment of alzheimer's disease | |
| GB201511453D0 (en) | Treatment of alzheimer's disease | |
| GB201800987D0 (en) | tHIRD alzheimer's treatment | |
| GB201800588D0 (en) | Third Alzheimer's Treatment |